ProfileGDS5678 / 1457396_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 36% 37% 40% 36% 38% 37% 36% 35% 37% 36% 37% 47% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9071238
GSM967853U87-EV human glioblastoma xenograft - Control 22.8179936
GSM967854U87-EV human glioblastoma xenograft - Control 32.8446537
GSM967855U87-EV human glioblastoma xenograft - Control 42.8752540
GSM967856U87-EV human glioblastoma xenograft - Control 52.7694636
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.950138
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8975237
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8128136
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7833135
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8291237
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.813136
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8107537
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1227347
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8238636